EUVIMEDEUVIMED entdecken
Multizentrische Studie

Efficacy of SABR in Uncommon Subtypes of Primary Kidney Cancer: An Analysis From the International Radiosurgery Oncology Consortium of the Kidney

Muhammad Ali, Rohann J M Correa, David Pryor, Braden Higgs, Swetha Sridharan, Mark Sidhom, Alexander Muacevic, Hiroshi Onishi, Anand Swaminath, William Grubb, Daniel X Yang, Aurelie Grant und 14 weitere

International Journal of Radiation Oncology*Biology*Physics · 2026

DOI: 10.1016/j.ijrobp.2025.08.043 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Muhammad Ali und 25 weiteren Autor:innen. Beteiligte Einrichtung: Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Victoria, Australia. Electronic ad…. Hauptthemen laut MEDLINE: Kidney Neoplasms, Radiosurgery, Carcinoma, Renal Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: While SABR is associated with excellent local control of primary renal cell carcinoma (RCC), outcomes based on clear cell RCC (ccRCC) and non-clear cell RCC (nccRCC) histologies are not well defined. This retropsective study's objective is to report the outcomes following SABR for uncommon subtypes of primary RCC. METHODS AND MATERIALS: Individual data of adult patients with biopsy-confirmed primary RCC receiving SABR between 2007 and 2021 from 16 institutions in Australia, Canada, Germany, Japan, and the USA were pooled. Patients with metastatic disease or upper tract urothelial carcinoma were excluded. The primary outcome was local failure (LF), based on the Response Evaluation Criteria in Solid Tumors version 1.1. Distant failure (DF), cancer-specific survival (CSS), treatment-related toxicity, and renal function changes following SABR were defined as secondary outcomes. Kaplan-Meier estimates were generated for LF, DF, and CSS stratified by ccRCC versus nccRCC histology, and compared using the log-rank test (for CSS) or Gray's test (for LF and DF). RESULTS: Two hundred eleven patients with a biopsy-confirmed ccRCC (n = 167) or nccRCC (n = 44) were included. In the nccRCC group, 59% (n = 26/44) and 11% (n = 5/44) were papillary and chromophobe histologies, respectively. Patients with nccRCC were more likely to be older (median age at SABR, 77.2 years vs 71.5; p = .009) and to be treated with multifraction SABR (82% [n = 36/44] vs 38% [n = 63/167]; p < .001) than the ccRCC group. The median follow-up was 4.02 years (IQR, 3.43-4.94) and 4.25 years (IQR, 3.02-5.00) for the ccRCC and nccRCC groups, respectively. The 5-year cumulative incidence of LF was 1.5% (95% CI, 0.3%-4.8%) in the ccRCC group versus 2.4% (95% CI, 0.2%-11.0%) in the nccRCC group (hazard ratio [HR], 0.90; 95% CI, 0.10-8.31; p = .922). The corresponding cumulative incidence of DF at 5 years was 6.0% in the ccRCC group versus 2.9% in the nccRCC group (HR, 0.34; 95% CI, 0.04-2.68; p = .304). The 5-year estimated CSS was 96.4% in the ccRCC group versus 96.4% in the nccRCC group (HR, 2.04; p = .561). From baseline, the mean ± SD estimated glomerular filtration rate reduced by 11.4 ± 13.4 mL/min at 3 years and by 12.2 ± 14.0 mL/min at 5 years. Sixteen patients (7.6%) experienced grade 2 or higher toxicities, with grade 2 fatigue (5.7%) being the most common. CONCLUSIONS: SABR provides excellent oncologic outcomes, irrespective of ccRCC or nccRCC histology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsRadiosurgeryCarcinoma, Renal CellHumansMaleFemaleAgedMiddle AgedAged, 80 and overTreatment OutcomeAdultKaplan-Meier Estimate

Autor:innen und Institutionen

  • Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, The University of Melbourne, Melbourne, Victoria, Australia. Electronic address: muhammad.ali@petermac.org.
  • London Health Sciences Centre, London, Ontario, Canada.
  • Department of Urology and Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, Brisbane, Queensland, Australia; Queensland University of Technology, Brisbane, Queensland, Australia.
  • Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia; University of South Australia, Adelaide, South Australia, Australia.
  • Department of Radiation Oncology, Calvary Mater Newcastle, Waratah, Newcastle, New South Wales, Australia.
  • Department of Radiation Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia; South West Sydney Clinical School, University of New South Wales, Sydney, New South Wales, Australia.

Zitieren

APA

Ali, M., Correa, R. J. M., Pryor, D., Higgs, B., Sridharan, S., Sidhom, M., Muacevic, A., Onishi, H., Swaminath, A., Grubb, W., Yang, D. X., Grant, A., Morgan, S. C., Ponsky, L., Cury, F. L., Teh, B. S., Lo, S. S., Mahadevan, A., Kaplan, I. D., …, & Siva, S. (2026). Efficacy of SABR in Uncommon Subtypes of Primary Kidney Cancer: An Analysis From the International Radiosurgery Oncology Consortium of the Kidney. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.08.043

Vancouver

Ali M, Correa RJM, Pryor D, Higgs B, Sridharan S, Sidhom M, et al. Efficacy of SABR in Uncommon Subtypes of Primary Kidney Cancer: An Analysis From the International Radiosurgery Oncology Consortium of the Kidney. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2025.08.043

BibTeX
@article{Ali2026,
  author = {Ali, Muhammad and Correa, Rohann J M and Pryor, David and Higgs, Braden and Sridharan, Swetha and Sidhom, Mark and Muacevic, Alexander and Onishi, Hiroshi and Swaminath, Anand and Grubb, William and Yang, Daniel X and Grant, Aurelie and Morgan, Scott C and Ponsky, Lee and Cury, Fabio L and Teh, Bin S and Lo, Simon S and Mahadevan, Anand and Kaplan, Irving D and Chu, William and Hannan, Raquibul and Staehler, Michael and Zaorsky, Nicholas G and Warner, Andrew and Louie, Alexander V and Siva, Shankar},
  title = {Efficacy of SABR in Uncommon Subtypes of Primary Kidney Cancer: An Analysis From the International Radiosurgery Oncology Consortium of the Kidney},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  doi = {10.1016/j.ijrobp.2025.08.043}
}
Kostenlos starten →